SSA
TVTX icon

Schonfeld Strategic Advisors’s Travere Therapeutics TVTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,872
Closed -$403K – 2595
2025
Q3 		$403K Sell
16,872
-39,451
-70% -$742K ﹤0.01% 1745
2025
Q2 		$834K Sell
56,323
-69,475
-55% -$1.15M 0.01% 1364
2025
Q1 		$2.25M Buy
125,798
+102,798
+447% +$2.09M 0.01% 906
2024
Q4 		$401K Sell
23,000
-152,820
-87% -$2.7M ﹤0.01% 1496
2024
Q3 		$2.46M Sell
175,820
-9,303
-5% -$96.9K 0.02% 801
2024
Q2 		$1.52M Sell
185,123
-255,834
-58% -$1.72M 0.01% 1025
2024
Q1 		$3.4M Sell
440,957
-288,052
-40% -$2.43M 0.02% 784
2023
Q4 		$6.55M Buy
729,009
+205,009
+39% +$1.49M 0.04% 452
2023
Q3 		$4.68M Buy
524,000
+218,371
+71% +$3.08M 0.04% 566
2023
Q2 		$4.69M Buy
305,629
+17,871
+6% +$325K 0.04% 505
2023
Q1 		$6.47M Buy
+287,758
New +$6.12M 0.06% 379
2022
Q4 		– Sell
-27,964
Closed -$689K – 3021
2022
Q3 		$689K Sell
27,964
-13,145
-32% -$340K 0.01% 1525
2022
Q2 		$996K Buy
41,109
+30,109
+274% +$757K 0.01% 1029
2022
Q1 		$284K Sell
11,000
-2,100
-16% -$55.8K ﹤0.01% 1726
2021
Q4 		$407K Buy
13,100
+3,400
+35% +$95.8K ﹤0.01% 1372
2021
Q3 		$235K Sell
9,700
-12,260
-56% -$225K ﹤0.01% 1683
2021
Q2 		$320K Buy
+21,960
New +$433K ﹤0.01% 1432
2021
Q1 		– Sell
-122,819
Closed -$3.35M – 2134
2020
Q4 		$3.35M Buy
+122,819
New +$2.87M 0.05% 494
2020
Q1 		– Sell
-141,489
Closed -$2.01M – 1536
2019
Q4 		$2.01M Buy
+141,489
New +$1.81M 0.05% 337
2019
Q2 		– Sell
-30,500
Closed -$691K – 1255
2019
Q1 		$691K Sell
30,500
-50,800
-62% -$1.12M 0.02% 609
2018
Q4 		$1.84M Sell
81,300
-19,700
-20% -$490K 0.07% 347
2018
Q3 		$2.9M Buy
+101,000
New +$2.89M 0.13% 215
2017
Q1 		– Sell
-30,418
Closed -$576K – 743
2016
Q4 		$576K Sell
30,418
-10,175
-25% -$208K 0.07% 314
2016
Q3 		$909K Buy
+40,593
New +$773K 0.15% 187

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's TVTX Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 16,872 shares — an estimated $403K sold.

Schonfeld Strategic Advisors first reported a position in TVTX in Q3 2016 and held it in 24 quarters. The position peaked at $6.55M in Q4 2023. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,872 Travere Therapeutics shares in Q4 2025, an estimated $403K.
  • Schonfeld Strategic Advisors first reported a position in Travere Therapeutics in Q3 2016 and held it in 24 quarters.
  • Schonfeld Strategic Advisors's Travere Therapeutics position peaked at $6.55M in Q4 2023.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.